TY - JOUR
T1 - Predicting cognitive decline
T2 - Which is more useful, baseline amyloid levels or longitudinal change?
AU - Chen, Gengsheng
AU - McKay, Nicole S.
AU - Gordon, Brian A.
AU - Liu, Jingxia
AU - Joseph-Mathurin, Nelly
AU - Schindler, Suzanne E.
AU - Hassenstab, Jason
AU - Aschenbrenner, Andrew J.
AU - Wang, Qing
AU - Schultz, Stephanie A.
AU - Su, Yi
AU - LaMontagne, Pamela J.
AU - Keefe, Sarah J.
AU - Massoumzadeh, Parinaz
AU - Cruchaga, Carlos
AU - Xiong, Chengjie
AU - Morris, John C.
AU - Benzinger, Tammie L.S.
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2024/1
Y1 - 2024/1
N2 - The use of biomarkers for the early detection of Alzheimer's disease (AD) is crucial for developing potential therapeutic treatments. Positron Emission Tomography (PET) is a well-established tool used to detect β-amyloid (Aβ) plaques in the brain. Previous studies have shown that cross-sectional biomarkers can predict cognitive decline (Schindler et al.,2021). However, it is still unclear whether longitudinal Aβ-PET may have additional value for predicting time to cognitive impairment in AD. The current study aims to evaluate the ability of baseline- versus longitudinal rate of change in-11C-Pittsburgh compound B (PiB) Aβ-PET to predict cognitive decline. A cohort of 153 participants who previously underwent PiB-PET scans and comprehensive clinical assessments were used in this study. Our analyses revealed that baseline Aβ is significantly associated with the rate of change in cognitive composite scores, with cognition declining more rapidly when baseline PiB Aβ levels were higher. In contrast, no signification association was identified between the rate of change in PiB-PET Aβ and cognitive decline. Additionally, the ability of the rate of change in the PiB-PET measures to predict cognitive decline was significantly influenced by APOE ε4 carrier status. These results suggest that a single PiB-PET scan is sufficient to predict cognitive decline and that longitudinal measures of Aβ accumulation do not improve the prediction of cognitive decline once someone is amyloid positive.
AB - The use of biomarkers for the early detection of Alzheimer's disease (AD) is crucial for developing potential therapeutic treatments. Positron Emission Tomography (PET) is a well-established tool used to detect β-amyloid (Aβ) plaques in the brain. Previous studies have shown that cross-sectional biomarkers can predict cognitive decline (Schindler et al.,2021). However, it is still unclear whether longitudinal Aβ-PET may have additional value for predicting time to cognitive impairment in AD. The current study aims to evaluate the ability of baseline- versus longitudinal rate of change in-11C-Pittsburgh compound B (PiB) Aβ-PET to predict cognitive decline. A cohort of 153 participants who previously underwent PiB-PET scans and comprehensive clinical assessments were used in this study. Our analyses revealed that baseline Aβ is significantly associated with the rate of change in cognitive composite scores, with cognition declining more rapidly when baseline PiB Aβ levels were higher. In contrast, no signification association was identified between the rate of change in PiB-PET Aβ and cognitive decline. Additionally, the ability of the rate of change in the PiB-PET measures to predict cognitive decline was significantly influenced by APOE ε4 carrier status. These results suggest that a single PiB-PET scan is sufficient to predict cognitive decline and that longitudinal measures of Aβ accumulation do not improve the prediction of cognitive decline once someone is amyloid positive.
KW - Alzheimer's disease
KW - Amyloid
KW - Cognition
KW - Longitudinal study
KW - PET
UR - http://www.scopus.com/inward/record.url?scp=85180939979&partnerID=8YFLogxK
U2 - 10.1016/j.nicl.2023.103551
DO - 10.1016/j.nicl.2023.103551
M3 - Article
C2 - 38150745
AN - SCOPUS:85180939979
SN - 2213-1582
VL - 41
JO - NeuroImage: Clinical
JF - NeuroImage: Clinical
M1 - 103551
ER -